Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment, Rezdiffra.
The launch of Madrigal Pharmaceuticals Inc.’s NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now has a market cap of close to $8 billion.
